Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Medipharm Labs Corp (OP: MEDIF )

0.0540 +0.0010 (+1.89%)
Streaming Delayed Price Updated: 10:15 AM EDT, Oct 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,204
Open 0.0530
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0530
Today's Range 0.0530 - 0.0550
52wk Range 0.0374 - 0.0747
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MEDIF Stock Earnings: MediPharm Labs Reported Results for Q2 2024
MediPharm Labs just reported results for the second quarter of 2024. 
Via InvestorPlace
MediPharm Q2 Loss Narrows, Adjusted EBITDA Climbs As Gross Profit Improves Nearly 300% YoY
Cannabinoids-focused pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Wednesday financial results for the second quarter ended June 30, 2024, revealing an... 
Via Benzinga
Topics Cannabis
Exposures Cannabis

Performance

YTD
+9.53%
+9.53%
1 Month
+14.16%
+14.16%
3 Month
+4.05%
+4.05%
6 Month
-5.59%
-5.59%
1 Year
-0.18%
-0.18%

More News

Read More
The Canadian Cannabis Report- Monday, Aug 12
Via Talk Markets
Topics Cannabis
Exposures Cannabis
This Cannabis Co With Significant Growth Potential And Other Hot Weed Stocks Soon To Report Earnings, What Investors Need To Know Now
Via Benzinga
Topics Cannabis
Exposures Cannabis
MEDIF Stock Earnings: MediPharm Labs Reported Results for Q1 2024
Via InvestorPlace
MEDIF Stock Earnings: MediPharm Labs Reported Results for Q4 2023
Via InvestorPlace
Executive Changes In Cannabis Industry You Should Know About, New Appointments & More
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabinoids-Focused MediPharm Boasts This Advanced Medical Cannabis Delivery Method
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabinoids-Focused Pharma Company, MediPharm, Sees Higher Q1 Revenue, CFO Touts 'Strong Financial Position'
Via Benzinga
The Canadian Cannabis Report - Monday, April 22
Via Talk Markets
Topics Cannabis
Exposures Cannabis
This Cannabinoids-Focused Pharma Co. Sees 50% YoY Surge In Revenue In 2023, Trims Losses
Via Benzinga
The Canadian Cannabis Report - Monday, March 25
Via Talk Markets
Topics Cannabis
Exposures Cannabis
Canadian CBD-Focused Pharma Co. Gets Green Light To Produce Medical Marijuana In Brazil
Via Benzinga
Topics Cannabis
Exposures Cannabis Product Safety
Key Leadership Changes In Cannabis You Should Know About As We Head Into 2024
Via Benzinga
Topics Cannabis
Exposures Cannabis
MediPharm Labs Still Hits C$8.5M Despite Sequential Drop, More On That In Q3 2023 Financial Report
Via Benzinga
New Cannabis Products Energize Global Health & Wellness Market, Including Australia
Via Benzinga
Topics Cannabis
Exposures Cannabis
MediPharm Settles Commercial Agreement Dispute With Tilray's Hexo For $9M
Via Benzinga
New CBD & THC Cannabis Oils Now Shipping To Australia From Canada
Via Benzinga
Topics Cannabis
Exposures Cannabis
The Canadian Cannabis Report - Monday, Sept. 25
Via Talk Markets
Topics Cannabis
Exposures Cannabis
MediPharm Labs Breaks Free From Royalty Agreement, What It Means & What's Next
Via Benzinga
Could Medical Cannabis Be The Answer For Fibromyalgia? Here's What New Study Found
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Stock Gainers And Losers From August 24, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Marijuana Stock Movers For August 23, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Stock Gainers And Losers From August 16, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Marijuana Stock Movers For August 15, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.